<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="125460">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01469221</url>
  </required_header>
  <id_info>
    <org_study_id>SPI-1012</org_study_id>
    <secondary_id>2011-003517-42</secondary_id>
    <nct_id>NCT01469221</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)</brief_title>
  <official_title>A Phase 3 International, Double-Bind Trial Evaluating Efficacy and Safety of Multiple Instillations of Intravesical Apaziquone vs. Placebo in Patients With Low-Intermediate Risk Non-Muscle Invasive Bladder Cancer (NMIBC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spectrum Pharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Spectrum Pharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an international, multicenter, double-blind, placebo-controlled, randomized study.
      All eligible patients entering the open label phase of the study will receive a single
      immediate instillation of apaziquone (4 mg in 40 mL diluent), post transurethral
      resection-bladder tumor (TURBT). Following Central Pathology review of histology and Double
      Blind Phase qualification, patients with confirmed eligibility will be randomized to receive
      either 6 weekly intravesical instillations of apaziquone or matching placebo and undergo
      cystoscopic and safety assessments every 3 months for 24 months. Patients with histologic
      evidence of recurrent disease during the study will be treated according to current
      treatment guidelines or local standard of care. Safety and efficacy assessments will be
      performed at 3 month intervals for all randomized patients throughout the study. Patients
      who receive single dose of apaziquone immediately following TURBT and are not eligible for
      randomization will be followed for 3 months by cystoscopic exam and safety assessments.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>July 2011</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Recurrence</measure>
    <time_frame>Recurrence of Cancer in the Bladder in 24 Months Follow-up</time_frame>
    <description>Time to recurrence (from randomization) for eligible patients with Low- intermediate risk NMIBC, who had undergone TURBT followed by, a single instillation of apaziquone immediately post TURBT and multiple instillations of apaziquone or placebo.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence Rate at 24 Months</measure>
    <time_frame>24 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrence Rate at 12 Months</measure>
    <time_frame>12 Months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression</measure>
    <time_frame>24 Months after Randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>24 Months after Randomization</time_frame>
    <description>Safety and Tolerability will be mainly characterized by the number and severity of treatment emergent adverse events and treatment related AEs that occur or worsen after the first dose of study treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">658</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Apaziquone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apaziquone</intervention_name>
    <description>Apaziquone 4 mg in 40 mL diluent</description>
    <arm_group_label>Apaziquone</arm_group_label>
    <other_name>EoQuin</other_name>
    <other_name>EO9</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Matching placebo in 40mL diluent</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (for Open Label):

          1. Has the patient given written informed consent and is the patient willing and able to
             abide by the protocol?

          2. Is the patient 18 years old or above?

          3. If the patient is a female of childbearing potential, is she using an
             acceptable/effective method of contraception?

          4. Does the female patient of childbearing potential have a negative serum pregnancy
             test at screening?

          5. Does the patient with clinically apparent primary or recurrent low grade Ta NMIBC
             have :

               -  multiple tumors (2-7)

               -  No single Tumor &gt; 3 cm

               -  No history / evidence of Tis

             Or does the patient with clinically apparent primary or recurrent high grade Ta NMIBC
             have:

               -  A single tumor that is ≤ 3 cm

               -  No history / evidence of Tis

          6. Is the patient able to retain bladder instillations for a minimum of 60 minutes (± 6
             minutes)?

          7. Did the patient have upper urinary tract evaluation to exclude urothelial carcinoma,
             hydronephrosis or renal cell carcinoma or other renal cancers in the 6 months prior
             to study screening?

          8. Is patient's urethra (including prostatic urethra in men) endoscopically free of any
             visible TCC?

          9. For patients with recurrent tumor, did the patient have at least a 6-month
             cystoscopically-confirmed tumor-free interval between the last tumor recurrence and
             the time of screening?

         10. Has the male patient with a prostate specific antigen (PSA) between 4 and 10 ng/mL
             had a diagnostic evaluation that reasonably excludes the diagnosis of prostate cancer
             in the opinion of the Investigator?

        Exclusion Criteria (for Open Label):

          1. Has the patient received any previous pelvic radiotherapy (includes external beam
             and/or brachytherapy)?

          2. Has the patient ever received apaziquone?

          3. Has the patient received an induction course (completed 5 of 6 scheduled weekly
             instillations) of intravesical BCG (± interferon) with the last dose given less than
             12 months ago?

          4. Has the patient had any prior intravesical chemotherapy, exclusive of single-dose
             adjuvant intravesical chemotherapy immediately post-TURBT?

          5. Does the patient have a history of urinary retention or a post void residual ≥ 250 cc
             by bladder scan or ultrasound (post void residual test may be repeated up to 3
             times)?

          6. Does the patient have or has the patient had any bladder tumor with histology other
             than transitional cell carcinoma?

          7. Does the patient have or has the patient had micro-papillary transitional cell
             carcinoma?

          8. If the patient has recurrent papillary disease of the bladder, has the pathology been
             anything other than pTa in the past?

          9. Does the patient have an active urinary tract infection confirmed by culture or a
             documented history of recurrent UTI (≥ 6 for females and ≥2 for males per year) in
             the prior 2 years?

         10. Does the patient have a bleeding disorder or a screening platelet count &lt; 50 x 109/L?

         11. Does the patient have a screening hemoglobin &lt; 10 g/dL?

         12. Does the male patient have a screening serum PSA &gt; 10 ng/mL?

         13. Does the patient have a history of Acquired Immunodeficiency Syndrome or HIV
             positive?

         14. Does the patient have a condition or a concurrent severe and/or uncontrolled medical
             or psychiatric disease (e.g., uncontrolled diabetes, decompensated congestive heart
             failure, myocardial infarction within 6 months of study, unstable and uncontrolled
             hypertension, or an active uncontrolled infection), which could compromise
             participation, compliance with scheduled visits and/or completion of the study?

         15. Has the patient participated in an investigational protocol within the past 90 days?

         16. Is the patient pregnant or breast feeding?

         17. Does the patient have a life expectancy of &lt;3 years?

         18. Has the patient had any other malignancy or received therapy for any malignancy in
             the last five years except

               -  non-melanoma skin tumors

               -  stage 0 (in situ) cervical carcinoma

               -  undetectable PSA for ≥1 year following definitive therapy for localized prostate
                  cancer?

         19. Does the patient have documented vesicoureteral reflux or an indwelling ureteral
             stent?

         20. Does the patient have tumor in a bladder diverticulum?

         21. Does the patient have a known allergy to red color food dye?

        Double-Blind Phase Inclusion Criteria

          1. Was all visible tumor resected at the initial TURBT?

          2. Does Central Pathology review of the patient's bladder tumor confirm:

               -  Low grade Ta disease for multiple tumors (2 - 7) or

               -  High Grade Ta disease for single tumor

               -  No microscopic evidence of lymphovascular invasion and/or evidence of tumor
                  thromboemboli
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Show-Li Sun, MD</last_name>
    <role>Study Director</role>
    <affiliation>Spectrum Pharmaceuticals, Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Tower Research Institute</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Urology, University of Miami Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Somerset Urological Associates, PA</name>
      <address>
        <city>Somerville</city>
        <state>New Jersey</state>
        <zip>08876</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associated Medical Professionals of New York, PLLC</name>
      <address>
        <city>Oneida</city>
        <state>New York</state>
        <zip>13421</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Male and Female Urology</name>
      <address>
        <city>Staten Island,</city>
        <state>New York</state>
        <zip>10314</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associated Medical Professionals of New York, PLLC</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance Urology Specialists</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nemocnice Jablonec nad Nisou, Urologické oddělení</name>
      <address>
        <city>Jablonec nad Nisou</city>
        <zip>466 60</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultní Thomayerova nemocnice s poliklinikou Urologické oddělení</name>
      <address>
        <city>Prague</city>
        <zip>14059</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Miejski im. Prof. E. Michałowskiego</name>
      <address>
        <city>Katowice</city>
        <zip>40-073</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CenterMed Kraków sp z o.o.</name>
      <address>
        <city>Kraków</city>
        <zip>31-530</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital Specjalistyczny im. Stefana Kardynała Wyszyńskiego Samodzielny Publiczny Zakład Opieki Zdrowotnej w Lublinie, Oddział Urologii i Onkologii Urologicznej</name>
      <address>
        <city>Lublin</city>
        <zip>20-718</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nieubliczny Zakład Opieki Zdrowotnej Europejskie Centrum Zdrowia Otwock im. Fryderyka Chopina Nieubliczny Zakład Opieki Zdrowotnej</name>
      <address>
        <city>Otwock</city>
        <zip>05-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zakład Opieki Zdrowotnej Pabianickie Centrum Medyczne</name>
      <address>
        <city>Pabianice</city>
        <zip>95-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Zakład Opieki Zdrowotnej, Wojewódzki Szpital Specjalistyczny nr 3</name>
      <address>
        <city>Rybnik</city>
        <zip>44-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital Specjalistyczny W Siedlcach</name>
      <address>
        <city>Siedlce</city>
        <zip>08-110</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pomorska Akademia Medyczna</name>
      <address>
        <city>Szczecin</city>
        <zip>70-111</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital Specjalistyczny im Janusza Korczaka</name>
      <address>
        <city>Słupsk</city>
        <zip>76-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medycznego Kształcenia Podyplomowego, Samodzielny Publiczny Szpital Kliniczny im. Prof. W. Orłowskiego</name>
      <address>
        <city>Warszawa</city>
        <zip>00-416</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojskowy Instytut Medyczny, Centralny Szpital Kliniczny MON</name>
      <address>
        <city>Warszawa</city>
        <zip>00-909</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Bielański im. ks. J. Popiełuszki Samodzielny Publiczny Zakład Opieki Zdrowotnej</name>
      <address>
        <city>Warszawa</city>
        <zip>01-809</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Kliniczny Dzieciątka Jezus - Centrum Leczenia Obrażeń</name>
      <address>
        <city>Warszawa</city>
        <zip>02-005</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Międzyleski Szpital Specjalistyczny w Warszawie Oddział Urologii</name>
      <address>
        <city>Warszawa</city>
        <zip>04-749</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wojewódzki Szpital Specjalistyczny we Wrocławiu, Ośrodek Badawczo Rozwojowy</name>
      <address>
        <city>Wrocław</city>
        <zip>51-124</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Niepubliczny Zakład Opieki Zdrowotnej-Centrum Medyczne Szpital Świętej Rodziny sp z o.o.</name>
      <address>
        <city>Łódź</city>
        <zip>90-302</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univerzitná nemocnica L. Pasteura Košice Univerzitná nemocnica L. Pasteura Košice</name>
      <address>
        <city>Košice</city>
        <zip>041 66</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univerzitná nemocnica Martin Urologická klinika</name>
      <address>
        <city>Martin</city>
        <zip>036 59</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultná nemocnica s poliklinikou J. A. Reimana Prešov Urologická klinika</name>
      <address>
        <city>Prešov</city>
        <zip>081 81</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultná nemocnica s poliklinikou Žilina Urologické oddelenie</name>
      <address>
        <city>Žilina</city>
        <zip>012 07</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>Poland</country>
    <country>Slovakia</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <lastchanged_date>June 2, 2015</lastchanged_date>
  <firstreceived_date>November 8, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bladder Cancer</keyword>
  <keyword>Non-Muscle Invasive Bladder Cancer</keyword>
  <keyword>NMIBC</keyword>
  <keyword>Apaziquone</keyword>
  <keyword>EOquin</keyword>
  <keyword>GU Cancer</keyword>
  <keyword>TURBT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Apaziquone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
